Tayma, 9, struggles with the most severe version of Epidermolysis Bullosa, a rare, agonizing disorder that causes skin to ...

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Following a launch last summer, Krystal Biotech’s topical gene therapy Vyjuvek is continuing to make waves in the dystrophic epidermolysis bullosa (DEB) disease space. During the most recent ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene geperpavec) to treat patients with the ultra-rare genetic blistering disease ...

DEB is a rare and severe disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1, which is responsible for the production of the protein ...